How p32/copper-mediating DLAT post-translational modification changes in ccRCC cells alter the mitochondrial metabolism and TCA cycle, and whether p32/copper combinational treatment can be used as drugs in cancer therapy with low adverse effects remain unsolved problems. This evidence concerns the gene C1QBP and nonpapillary renal cell carcinoma.